TBL1XR1-JAK2: a novel fusion in a pediatric T cell acute lymphoblastic leukemia patient with increased absolute eosinophil count

AbstractT-lymphoblastic leukemia/lymphoma (T-ALL/LBL) with anyJAK2 gene fusion is rarely reported. Here, we report a case of T-ALL with a novelTBL1XR1-JAK2 gene fusion in a 5-year-old boy. His lab showed a high white blood cell count, mild anemia, moderate thrombocytopenia, and concurrently increased eosinophils (absolute eosinophil count: 4  × 10^9/L). Peripheral blood and bone marrow aspirate smears showed>  90% mononucleated blasts. Flow cytometry on peripheral blood revealed a large blast population positive for CD2, surface CD3 (<  25%), CD10 (50%), CD5, CD7, CD4, CD8, TdT, CD1a (60%), and CD45. Conventional karyotype analysis showed t(3;9)(q26;p24) and t(11;14)(p13;q11.2)/TCRD-LMO2. Next-generation sequencing (NGS) identified a novelTBL1XR1-JAK2 gene fusion in a sequencing depth of 180  × by RNAseq,FBXW7 R465H mutation, and loss of exons 2 –3 ofCDKN2A/B by DNAseq. Follow-up bone marrow aspirate on day-28 post-induction therapy revealed no morphologic evidence of residual leukemia. We believe that theTBL1XR1-JAK2 fusion may behave in a similar functional manner to thePCM1-JAK2 fusion gene and constitutes a new variant of this family and a potential target of tyrosine kinase inhibitor (TKI) therapy.
Source: Journal of Hematopathology - Category: Pathology Source Type: research